Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
Mitigating Vasomotor Symptoms from Adjuvant Endocrine Therapy
Vasomotor symptoms — hot flashes and night sweats — are commonly reported by patients, both men and women, who receive adjuvant endocrine therapy for early-stage breast cancer. In many cases, these symptoms significantly impact quality of life, leading to nonadherence, noncompliance, and early discontinuation of therapy. Most of the numerous strategies for mitigating vasomotor symptoms, including low-dose antidepressants, acupuncture, and herbal products, have limited to no efficacy.
Q-122 is a nonhormonal, orally available compound that is postulated to affect activation of specific estrogen-responsive neurons in the hypothalamus responsible for vasomotor symptoms. Investigators conducted an industry-funded, multinational, double-blind, randomized, controlled phase 2 trial of Q-122 in women on adjuvant endocrine therapy who experienced 50 or more self-reported moderate-to-severe hot flashes and night sweats per week. Patients received Q-122 or placebo twice daily for 28 days.
Of 131 patients, median age was 54.9 years and mean body-mass index was 29.3 kg/m2. The distribution of adjuvant endocrine therapy was similar between the two groups (~41% aromatase inhibitor; ~59% tamoxifen or toremifene). The primary outcome, mean percentage change from baseline in the number of vasomotor events, was greater in patients receiving Q-122 compared with placebo (−39% vs. −26%). The most frequent treatment-related adverse events were hot flashes, diarrhea, and urinary tract infection. Some quality-of-life domains, including sleep, leisure, and social activities, were improved in patients receiving Q-122.
To reap the benefits of adjuvant endocrine therapy, it is imperative to optimize patient compliance and adherence by minimizing side effects. Q-122 shows promise in reducing the intensity and frequency of vasomotor symptoms.
Vrselja A et al.
Title: Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: A phase 2, randomised, double-blind, placebo-controlled trial.
Source: Lancet 2022 Nov 12; [e-pub]. (Abstract/FREE Full Text)